Highbridge Capital Management

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Wednesday, March 27, 2024
Capacity utilization, Diagnosis, Research, RSA, Bone marrow, TCT, Rituximab, Cell, General counsel, Health, Patient, EAP, Highbridge Capital Management, Society, Ronald Reagan, ATM, Depreciation, ID, Transplant, Therapy, Medicare, NK, CMS, Marketing, UCLA Health, Dentistry

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Gamida Cell will become a private company, wholly owned by Highbridge, and the company’s outstanding ordinary shares are expected to be canceled.
  • The company has confirmed coverage with payers who cover more than 90% of commercial lives, exceeding the 2023 goal of 70%.
  • The full year Net Revenue included $1.1 million of net review for the fourth quarter of 2023.

Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management

Retrieved on: 
Wednesday, March 27, 2024
RSA, Cell, Herzog, Fox & Ne'eman, Patient, LLP, Highbridge Capital Management, King & Spalding, Cooley LLP, Therapy, Bank

BOSTON and NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that it has entered into a Restructuring Support Agreement (the “RSA” or “transaction”) with certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), the Company’s principal lender. The transaction is anticipated to provide Gamida Cell with a long-term financial runway and support the ongoing commercialization of Omisirge® (omidubicel-onlv) and is expected to be completed through a voluntary Israeli restructuring proceeding.

Key Points: 
  • “In March 2023, Gamida Cell embarked on an extensive strategic process to address its capital structure and liquidity constraints by partnering Omisirge with a third party,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
  • The Company will receive $30 million of new capital from Highbridge on the effective date of the restructuring.
  • Gamida Cell will become a private company, wholly owned by Highbridge, and the Company’s outstanding ordinary shares are expected to be canceled.
  • “Despite Gamida Cell’s financial struggles, we believe in the potential of Omisirge to fulfill an important unmet need in stem cell transplant,” said Jonathan Segal, Co-Chief Investment Officer at Highbridge Capital Management.

Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors

Retrieved on: 
Monday, December 18, 2023
Gibson Dunn, Highbridge Capital Management, Ropes & Gray, Davidson Kempner Capital Management, SAN, Therapy, King & Spalding, Serri, Sardinia, Security (finance)

SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with institutional investors Athyrium Capital Management, Davidson Kempner Capital Management, and Highbridge Capital Management to reduce the company’s net debt by 60% through a convertible note exchange which also brings $16.7 million in new capital.

Key Points: 
  • SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with institutional investors Athyrium Capital Management, Davidson Kempner Capital Management, and Highbridge Capital Management to reduce the company’s net debt by 60% through a convertible note exchange which also brings $16.7 million in new capital.
  • Between the note exchange implemented in September and today’s transaction, we achieved a 75% overall reduction in net debt.
  • This represents substantial progress toward our goal to optimize our capital structure to align with the current company profile,” said Eric d’Esparbes, Chief Financial Officer of Biora Therapeutics.
  • “The additional capital investment from three established institutional investors demonstrates continued support for our innovative technologies.

The J.M. Kaplan Fund Names Julia Bator as New Executive Director

Retrieved on: 
Friday, November 17, 2023
Chancellor, Cuban literacy campaign, Public school, Glen Mills Schools, Climate change, Fund, City Parks Foundation, Ascend, Investment, Bator, Highbridge Capital Management, Pioneer Works, Advocacy, Culture, Review Board, LaGuardia Airport, Trustee, Government, Education, Management

Kaplan Fund is pleased to welcome Julia Bator as its new Executive Director.

Key Points: 
  • Kaplan Fund is pleased to welcome Julia Bator as its new Executive Director.
  • Bator, a proven executive and visionary philanthropic advisor, brings extensive leadership experience in foundations, nonprofit organizations, and government to the Fund.
  • Kaplan Fund as a champion and supporter of its grantees – and as a good neighbor in New York City," Bator said.
  • "I'm honored to carry forward that legacy as their next Executive Director and energized by the challenges and opportunities ahead."

Veritone Reports Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 8, 2023
Software, Technology, Artificial Intelligence, U.S. Women's National Team Players Association, Government, Veritone, Unitary state, A&E Networks, Football, Prior, Branch, HBO, Pro forma, GAAP, Managed services, Senior, Common stock, U.S. Department of Justice Office of Legislative Affairs, NBCUniversal, NBC, Indian Revenue Service (Custom & Indirect Taxes), Revenue stream, Augusta National Golf Club, Legislative Branch Appropriations Act, 2015, Association football, Partnership, CareerBuilder, Term loan, Consumer surplus for software products, Human voice, Universal, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, CAA, United States Tennis Association, Highbridge Capital Management, Letter, DOJ, Software as a service, Sales, Video game, Renting, Security (finance), Music, United States Soccer Federation, Service, Vicia faba, Amazon

Veritone may, subject to certain conditions and limitations, elect to make any amortization payment in shares of its common stock.

Key Points: 
  • Veritone may, subject to certain conditions and limitations, elect to make any amortization payment in shares of its common stock.
  • Financial Results for Three Months Ended September 30, 2023
    Delivered third quarter revenue of $35.1 million, a decrease of $2.1 million or 6% from $37.2 million in the third quarter of 2022.
  • Veritone will hold a conference call using its synthetic voice technology, Veritone Voice, to deliver management’s prepared remarks on Wednesday, November 8, 2023, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss its third quarter 2023 results, provide an update on the business and conduct a question-and-answer session.
  • To participate, please join the audio webcast or dial-in and ask to be connected to the Veritone earnings conference call.

Capricor Therapeutics Announces $23 Million Registered Direct Offering

Retrieved on: 
Friday, September 29, 2023
Attention, Capital market, Exosome, Enterprise file synchronization and sharing, Research, Sale, Highbridge Capital Management, Prospectus, SAN, MUSCULAR, Form, Security (finance), Therapy

for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering.

Key Points: 
  • for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering.
  • Each warrant will be exercisable beginning six months after issuance and will expire seven years from the date of issuance.
  • The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from the offering are expected to be approximately $23 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

Retrieved on: 
Wednesday, July 19, 2023
Highbridge Capital Management, Treasury, Vamorolone, Catalyst Pharmaceuticals, Highbridge, Partnership, Duchenne muscular dystrophy, European Medicines Agency, Sale, EMA, U.S. FDA, Acquisition, Patient, PDUFA, Hart–Scott–Rodino Antitrust Improvements Act, FDA, Pharmaceutical industry, Security (finance), DMD, Catalysis

53 LR

Key Points: 
  • 53 LR
    Pratteln, Switzerland, July 19, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of the exclusive license agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), announced on June 20, 2023 [1].
  • The license agreement grants Catalyst commercialization rights in North America (NA) for vamorolone in Duchenne muscular dystrophy (DMD) and all potential future indications for a total consideration to Santhera of up to USD 231 million plus royalty payments from product sales.
  • Outside the core European countries where Santhera will commercialize vamorolone directly, the Company seeks partnerships and has granted Catalyst a right of first negotiation in partnering discussions.
  • Closing of the transaction was subject to customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

CoinFund Reinforces Commitment to Web3 Technology with the Close of $158M Seed IV Fund

Retrieved on: 
Tuesday, July 18, 2023
Technology, Finance, Security, Fintech, Professional Services, Digital Cash Management, Digital Assets, Blockchain, Web3, Artificial Intelligence, Cosmos, Neutron, Ethereum, CESR, Cloudburst, American Capital, Dame Alice Owen's School, Internet, Head, POS, Communication, Decentralized finance, Index, Amazon, Highbridge Capital Management, Non-fungible token, Investment, Ministry of National Education (France), Growth, Entrepreneurship, CIO, Ecosystem, AI, Fund, Cryptocurrency, Gustne Gensyn

CoinFund , a leading cryptonative investment firm and registered investment adviser, today announces the close of $158 million (M) CoinFund Seed IV Fund LP (“Seed IV” or “The Fund”), backed by a combination of sophisticated institutional investors, family offices, and high net worth individuals.

Key Points: 
  • CoinFund , a leading cryptonative investment firm and registered investment adviser, today announces the close of $158 million (M) CoinFund Seed IV Fund LP (“Seed IV” or “The Fund”), backed by a combination of sophisticated institutional investors, family offices, and high net worth individuals.
  • CoinFund Seed IV LP exceeded its initial target fundraising goal of $125M.
  • The Fund will support pre-seed and seed stage investments in new and ambitious founding teams across the web3 ecosystem.
  • The close of Seed IV comes after the recent announcement of CESR , the composite ether staking rate, announced by CoinFund in collaboration with CoinDesk Indices.

Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Monday, May 15, 2023
FDA, Health, Stem Cells, Partnership, Therapy, Centers for Medicare & Medicaid Services, Cell, Medicare, Highbridge Capital Management, ATM, Patient, Boxed warning, Bone marrow, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Hematopoietic stem cell transplantation, Food, Mobile phone, Pharmaceutical industry, Security (finance), Video game, Cryptocurrency

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the quarter ended March 31, 2023.
  • As of May 15, 2023:
    The company is on target to complete the goal of onboarding 10-15 of the top 70 transplant centers in 2023.
  • Commercial expenses were $5.6 million in the first quarter of 2023, compared to $3.9 million in the first quarter of 2022.
  • As of March 31, 2023, Gamida Cell had total cash and cash equivalents of $46.8 million.

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
Monday, March 27, 2023
Research, Clinical Trials, Health Technology, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Haematopoiesis, Ministry of Health (Israel), EAP, University, ASH, Therapy, Integrin alpha-1, CD16, T&E, CD57, Neoplasm, Survival, NK, Toxicity, Tandem, Cell, IP, Rated R, LAMP1, TCT, Ministry, Incidence, Highbridge Capital Management, Center for International Blood and Marrow Transplant Research, LAG3, Patient, CD56, University of Minnesota Medical School, CD62L, PDUFA, Viral, Poster, FDA, Society, Safety, Cryptocurrency, Pharmaceutical industry, Dentistry, Vaccine, Security (finance), Transplant

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022.
  • As of December 31, 2022, Gamida Cell had total cash and cash equivalents of $64.7 million.
  • “Our mission is to bring potentially curative therapies to patients,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
  • Especially since our engineered NK cell therapy candidates, which are derived from healthy donors, have demonstrated encouraging pre-clinical data that differentiate them from other NK cell therapy approaches.